A compound of formula: wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A 15 is: each H 14 is independently a fused unsaturated, partially unsaturated or saturated tricyclic carbocycle which is optionally substituted with one or more groups independently selected from R A1 and R A3; and each X A is independently O, NR, SO, SO 2 C(=O), NRC(=O), C(=O)NR, CR=CR, NRC(=O)NR, allenyl, alkynyl, or absent; each R is independently selected from H or alkyl; each R A1 is independently selected from cyano, nitro, SOR 4, SO 2 R 4, -alkylSO 2 R 4, haloalkoxy, cyanoalkyl, NR 4 SO 2 R 4, cycloalkyl, (halo)cycloalkyl, heterocycle, (cycloalkyl)alkyl, (heterocycle)alkyl, wherein each alkyl, heterocycle and cycloalkyl is optionally substituted with one or more halo; each R A3 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, -NR a R b, (NR a R b)alkyl, and (NR a R b)carbonyl; R a and R b are each independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyl, aryl, arylalkyl, arylalkylcarbonyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; each R 4 is independently selected from H, alkyl, haloalkyl, aryl, and arylalkyl; and each P is independently selected from: or a pharmaceutically acceptable salt thereof. V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A 15 is: each H 14 is independently a fused unsaturated, partially unsaturated or saturated tricyclic carbocycle which is optionally substituted with one or more groups independently selected from R A1 and R A3; and each X A is independently O, NR, SO, SO 2 C(=O), NRC(=O), C(=O)NR, CR=CR, NRC(=O)NR, allenyl, alkynyl, or absent; each R is independently selected from H or alkyl; each R A1 is independently selected from cyano, nitro, SOR 4, SO 2 R 4, -alkylSO 2 R 4, haloalkoxy, cyanoalkyl, NR 4 SO 2 R 4, cycloalkyl, (halo)cycloalkyl, heterocycle, (cycloalkyl)alkyl, (heterocycle)alkyl, wherein each alkyl, heterocycle and cycloalkyl is optionally substituted with one or more halo; each R A3 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, -NR a R b, (NR a R b)alkyl, and (NR a R b)carbonyl; R a and R b are each independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyl, aryl, arylalkyl, arylalkylcarbonyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; each R 4 is independently selected from H, alkyl, haloalkyl, aryl, and arylalkyl; and each P is independently selected from: or a pharmaceutically acceptable salt thereof. each H 14 is independently a fused unsaturated, partially unsaturated or saturated tricyclic carbocycle which is optionally substituted with one or more groups independently selected from R A1 and R A3; and each X A is independently O, NR, SO, SO 2 C(=O), NRC(=O), C(=O)NR, CR=CR, NRC(=O)NR, allenyl, alkynyl, or absent; each R is independently selected from H or alkyl; each R A1 is independently selected from cyano, nitro, SOR 4, SO 2 R 4, -alkylSO 2 R 4, haloalkoxy, cyanoalkyl, NR 4 SO 2 R 4, cycloalkyl, (halo)cycloalkyl, heterocycle, (cycloalkyl)alkyl, (heterocycle)alkyl, wherein each alkyl, heterocycle and cycloalkyl is optionally substituted with one or more halo; each R A3 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, -NR a R b, (NR a R b)alkyl, and (NR a R b)carbonyl; R a and R b are each independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyl, aryl, arylalkyl, arylalkylcarbonyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; each R 4 is independently selected from H, alkyl, haloalkyl, aryl, and arylalkyl; and each P is independently selected from: or a pharmaceutically acceptable salt thereof.